Reviva Pharmaceuticals Announces Positive Safety Data from Drug-Drug Interaction Clinical Study of BrilaroxazineGlobeNewsWire • 12/15/22
Reviva Pharmaceuticals Announces Canadian Composition of Matter Patent for Triple Reuptake Inhibitor RP1208GlobeNewsWire • 11/21/22
Reviva Pharmaceuticals Holdings, Inc. Reports Third Quarter 2022 Financial Results and Recent Business HighlightsGlobeNewsWire • 11/14/22
Reviva Pharmaceuticals Announces Global Enrollment Update for Pivotal Phase 3 RECOVER Study Evaluating Brilaroxazine for SchizophreniaGlobeNewsWire • 10/31/22
Reviva Pharmaceuticals to Present at the Lytham Partners Fall 2022 Investor ConferenceGlobeNewsWire • 09/26/22
Reviva Pharmaceuticals to Present at the H.C. Wainwright 24th Annual Global Investment ConferenceGlobeNewsWire • 09/07/22
Reviva Pharmaceuticals Holdings, Inc. Announces $8.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq RulesGlobeNewsWire • 09/06/22
Reviva Pharmaceuticals Holdings, Inc. Reports Second Quarter 2022 Financial Results and Recent Business HighlightsGlobeNewsWire • 08/15/22
Reviva Pharmaceuticals to Participate in the 2022 BIO International ConventionGlobeNewsWire • 06/02/22
Reviva Pharmaceuticals to Present at the H.C. Wainwright Global Investment ConferenceGlobeNewsWire • 05/17/22
Reviva Pharmaceuticals Holdings, Inc. Reports First Quarter 2022 Financial Results and Recent Business HighlightsGlobeNewsWire • 05/16/22
Reviva Pharmaceuticals Announces Update on RECOVER, a Pivotal Phase 3 Global Study Evaluating Brilaroxazine for the Treatment of SchizophreniaGlobeNewsWire • 05/03/22
Reviva Pharmaceuticals Holdings, Inc. Interview to Air on Bloomberg U.S. on the RedChip Money Report®GlobeNewsWire • 03/24/22
Reviva Pharmaceuticals Holdings, Inc. to Participate at the Maxim Virtual Growth ConferenceGlobeNewsWire • 03/22/22
Reviva Pharmaceuticals Holdings, Inc. to Present at Upcoming Virtual Investor ConferencesGlobeNewsWire • 03/18/22
Reviva Pharmaceuticals Holdings, Inc. Reports Full Year 2021 Financial Results and Recent Business HighlightsGlobeNewsWire • 03/15/22
Reviva Pharmaceuticals Announces First Patients Dosed in Pivotal Phase 3 Study and Long-Term Safety Trial Evaluating Brilaroxazine for the Treatment of SchizophreniaGlobeNewsWire • 02/01/22
Reviva Pharmaceuticals Holdings, Inc. Receives FDA May Proceed Letter for Pivotal Phase 3 Clinical Trial and Long-Term Safety Trial Evaluating Brilaroxazine For The Treatment of SchizophreniaGlobeNewsWire • 01/10/22
Reviva Pharmaceuticals to Participate in the Upcoming January Virtual Investor ConferencesGlobeNewsWire • 12/20/21
Reviva Pharmaceuticals Holdings, Inc. Reports Third Quarter 2021 Financial Results and Recent Business HighlightsGlobeNewsWire • 11/15/21